Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502057 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6505346 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6505341 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6501099 | 0.88 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6501100 | 0.88 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6498435 | 0.87 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6498440 | 0.87 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6507001 | 0.87 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6507005 | 0.87 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 | |
| SCHEMBL6508936 | 0.84 | HDAC1 (1.00) | HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005065681-A1 | N- HYDROXY-3-(3-(1H-IMIDAZOL-2-YL)-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050159470-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-07-21 | — | — | US | claimed |
| WO-2005065681-A1 | N- HYDROXY-3-(3-(1H-IMIDAZOL-2-YL)-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065681-A1 | N- HYDROXY-3-(3-(1H-IMIDAZOL-2-YL)-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050159470-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159470-A1 | Histone deacetylase inhibitors | HDAC5, HDAC1, HDAC10 | HDAC1 2/4885HDAC8 6/4885HDAC6 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.